Rifaquizinone

Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci[1][2].

Product Specifications

CAS Number

[922717-97-3]

Product Name Alternative

CBR-2092; TNP-2092

UNSPSC

12352005

Target

Antibiotic; Bacterial; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/rifaquizinone.html

Solubility

10 mM in DMSO

Smiles

CN(C1CCN(CC1)/N=C/C2=C3C(O)=C4C(C5=C(O[C@@](C5=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(C(N3)=O)/C)C)O)C)O)C)OC(C)=O)C)OC)C)C(C)=C4O)=C2O)C6([C@@]7([H])CN(C8=C(C9=C(C%10CC%10)C=C(C(N9C=C8F)=O)C(O)=O)C)CC7)CC6

Molecular Formula

C65H81FN6O15

Molecular Weight

1205.37

References & Citations

[1]Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jul;52 (7) :2313-23.|[2]Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 2008 Jul;52 (7) :2324-34.